# A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

> **NCT05662332** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 795 (actual)

## Conditions studied

- Type 2 Diabetes
- T2D

## Interventions

- **DRUG:** Insulin Efsitora Alfa
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT05662332
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-14
- **Primary completion:** 2024-07-19
- **Final completion:** 2024-07-19
- **Target enrollment:** 795 (ACTUAL)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662332, "A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05662332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*